What is Apicore US?
Apicore US is a privately held company based in New Jersey, specializing in the development and manufacturing of niche Active Pharmaceutical Ingredients (APIs) and pharmaceuticals. The company boasts a portfolio including over 15 Abbreviated New Drug Applications (ANDAs), with one in partnership with Medicure. Apicore manufactures more than 100 different APIs, with a substantial number having Drug Master Files submitted to the FDA and approved for commercial sale in the U.S. by its clients. The company focuses on complex synthesis and high-value APIs for both domestic and international generic and branded pharmaceutical firms. Apicore operates two FDA-approved manufacturing facilities: one in Somerset, New Jersey, capable of producing volumes from grams to 200 kg, and another in Vadodara, Gujarat, India, with a capacity of a few kilograms up to 60 metric tons annually. Both sites are equipped with advanced analytical and research infrastructure.
How much funding has Apicore US raised?
Apicore US has raised a total of $16.7M across 3 funding rounds:
Unspecified
$6.8M
Unspecified
$9.2M
Private Equity
$720K
Unspecified (2014): $6.8M with participation from Undisclosed
Unspecified (2014): $9.2M led by Undisclosed
Private Equity (2016): $720K, investors not publicly disclosed
What's next for Apicore US?
The recent major strategic investment in Apicore US signals a pivotal phase for the company, likely aimed at expanding its manufacturing capacity, accelerating the development of its API pipeline, and potentially broadening its market reach. Given the company's focus on difficult-to-synthesize and high-value APIs, this capital infusion is expected to bolster its research and development efforts and enhance its competitive edge in the pharmaceutical ingredients market. The enterprise-level funding context suggests a strategic move towards scaling operations and solidifying its position as a key supplier to pharmaceutical companies worldwide.
See full Apicore US company page
